Business Context and Reporting Period
Alector, Inc. (ALEC), a Delaware corporation, filed this Form 8-K on November 14, 2024. The filing reports the entry into a material definitive agreement to secure a senior secured term loan facility to support working capital and general corporate purposes.
Key Financial Metrics and Debt Structure
- Total Facility Size: Up to $50.0 million in aggregate principal amount, available in up to two tranches.
- Initial Draw: $10.0 million borrowed on the Closing Date (November 14, 2024).
- Tranche Availability:
- Tranche 1: Up to $25.0 million available through June 30, 2026.
- Tranche 2: Up to $25.0 million available at the sole discretion of the Lenders.
- Interest Rate: The greater of (A) Prime Rate + 1.05% or (B) 8.05%.
- Repayment Terms: Monthly interest-only payments until December 1, 2026. Principal and interest repayable in equal monthly installments thereafter until maturity on December 1, 2028.
- Collateral: Secured by substantially all assets, including intellectual property, with specific exceptions for existing agreements with AbbVie, Adimab, and Glaxo Wellcome.
- Upfront Costs: $250,000 initial facility charge paid on the Closing Date.
Material Changes and Covenants
The filing represents a material change in the company's capital structure through the incurrence of new debt. The Loan Agreement includes customary affirmative and negative covenants restricting the company's ability to:
- Dispose of assets or enter into certain licensing arrangements.
- Effect mergers, incur additional debt, or grant liens.
- Pay dividends or distributions on capital stock.
- Make investments or acquisitions.
Events of default include payment defaults, breaches of covenants, bankruptcy, and material adverse effects, which could trigger acceleration of obligations and a 5% interest rate penalty.
Prepayment Terms and Contingencies
The Borrowers may prepay the Term Loans subject to the following premiums and end-of-term charges:
- Prepayment Premiums:
- 2.0% if prepaid within 12 months of Closing.
- 1.5% if prepaid between 12 and 24 months.
- 0.5% if prepaid after 24 months but prior to Maturity.
- End of Term Charge:
- 2.45% if prepaid/repaid within the first 24 months.
- 4.75% if prepaid/repaid after 24 months (including at Maturity).
- Extension Option: The interest-only period may be extended by up to 24 months subject to achieving certain milestones.
Note: This filing does not provide revenue, profit, cash flow, or margin data. It focuses exclusively on the debt facility.
Investor Verification Checklist
- Verify the company's current cash position and burn rate to assess the necessity of the $10.0 million initial draw.
- Review the specific "milestones" required to extend the interest-only period beyond December 1, 2026.
- Confirm the status of the intellectual property exceptions (AbbVie, Adimab, Glaxo Wellcome) to understand the scope of collateral.
- Monitor the Prime Rate to calculate the actual interest expense, as the rate is variable (Prime + 1.05% vs. 8.05% floor).
- Check for any subsequent filings regarding the drawdown of the remaining $15.0 million of Tranche 1 or the discretionary Tranche 2.